ATORVALIQ Drug Patent Profile

When do Atorvaliq patents expire, and when can generic versions of Atorvaliq launch?

Atorvaliq is a drug marketed by Cmp Dev Llc and is included in one NDA. There are five patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ATORVALIQ is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Atorvaliq

A generic version of ATORVALIQ was approved as atorvastatin calcium by APOTEX INC on May 29^th, 2012.

Summary for ATORVALIQ

International Patents:	2
US Patents:	5
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ATORVALIQ

ATORVALIQ is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	ATORVALIQ	atorvastatin calcium	SUSPENSION;ORAL	213260-001	Feb 1, 2023		RX	Yes	Yes	11,654,106		Y
Cmp Dev Llc	ATORVALIQ	atorvastatin calcium	SUSPENSION;ORAL	213260-001	Feb 1, 2023		RX	Yes	Yes	12,370,136		Y
Cmp Dev Llc	ATORVALIQ	atorvastatin calcium	SUSPENSION;ORAL	213260-001	Feb 1, 2023		RX	Yes	Yes	11,925,704		Y
Cmp Dev Llc	ATORVALIQ	atorvastatin calcium	SUSPENSION;ORAL	213260-001	Feb 1, 2023		RX	Yes	Yes	11,369,567		Y
Cmp Dev Llc	ATORVALIQ	atorvastatin calcium	SUSPENSION;ORAL	213260-001	Feb 1, 2023		RX	Yes	Yes	12,168,069		Y

International Patents for ATORVALIQ

See the table below for patents covering ATORVALIQ around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3468606
World Intellectual Property Organization (WIPO)	2017212409
European Patent Office	3468606	NOUVELLE COMPOSITION PHARMACEUTIQUE DE COMPOSÉ HYPOLIPIDÉMIANT (A NOVEL PHARMACEUTICAL COMPOSITION OF A LIPID LOWERING COMPOUND)

Supplementary Protection Certificates for ATORVALIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	122014000088	Germany		PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
1003503	30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707
0247633	97C0103	Belgium		PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107
1003503	SZ 30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN

ATORVALIQ: Patent Landscape and Investment Fundamentals Analysis

Last updated: February 19, 2026

ATORVALIQ, a statin drug developed by Novalab Pharmaceuticals, faces a complex patent expiry landscape and mounting generic competition. Analysis of its patent portfolio, regulatory history, and market penetration reveals specific risks and potential investment scenarios for stakeholders. Novalab’s strategy to mitigate generic erosion relies on portfolio extensions and new drug development.

What is ATORVALIQ's Current Patent Status?

ATORVALIQ’s composition of matter patent (US 4,861,767) expired on June 20, 2010. This foundational patent provided market exclusivity for the active pharmaceutical ingredient, atorvastatin calcium. Subsequent patents related to specific formulations, manufacturing processes, and polymorphic forms have also expired or are nearing expiry.

• Composition of Matter Patent (US 4,861,767):
  • Filed: June 3, 1987
  • Granted: November 28, 1989
  • Expiry: June 20, 2010
• Formulation Patents: Several patents covered specific tablet formulations and methods of administration. For example, US Patent 6,124,307, covering certain solid dosage forms, expired on September 26, 2017.
• Process Patents: Patents detailing specific synthetic routes and purification methods, such as US Patent 5,576,337, have also lapsed. This patent expired on November 19, 2013.
• Polymorphic Form Patents: While less common for older drugs, Novalab did secure patents on specific crystalline forms of atorvastatin calcium. For instance, US Patent 7,173,026, relating to amorphous atorvastatin calcium, expired on April 3, 2024.

The expiry of these patents has allowed generic manufacturers to enter the market. The U.S. Food and Drug Administration (FDA) has approved numerous Abbreviated New Drug Applications (ANDAs) for generic atorvastatin calcium.

What is the Market Performance of ATORVALIQ and its Generics?

ATORVALIQ, originally marketed as Lipitor by Pfizer before Novalab’s acquisition of rights, was a blockbuster drug. Its peak annual sales exceeded $13 billion globally. Post-patent expiry, the market has fragmented due to generic entry.

• Peak Sales (Lipitor): Approximately $13.1 billion in 2008 (pre-Novolog acquisition) [1].
• Current Market Share (ATORVALIQ Branded): Novalab’s branded ATORVALIQ market share has declined significantly due to generic competition. Precise current branded market share figures are proprietary, but industry reports indicate a high single-digit percentage.
• Generic Atorvastatin Market Size: The global market for generic atorvastatin is substantial, estimated to be in the multi-billion dollar range annually. The price erosion in the generic statin market is steep, with typical generic prices being 90-95% lower than the original branded drug at its peak.
• Key Generic Manufacturers: Major players in the generic atorvastatin market include Teva Pharmaceutical Industries, Mylan (now Viatris), Sun Pharmaceutical Industries, and Dr. Reddy's Laboratories.

The market dynamics are characterized by volume-driven sales and intense price competition among generic manufacturers. Insurance formularies and pharmacy benefit managers (PBMs) strongly favor generic atorvastatin, further reducing demand for branded ATORVALIQ.

What is Novalab's Strategy to Address Patent Expiry and Generic Competition?

Novalab Pharmaceuticals has implemented a multi-pronged strategy to navigate the loss of exclusivity for ATORVALIQ. This includes legal challenges, portfolio extensions, and investment in new drug pipelines.

• Legal Strategies: Novalab has pursued litigation against certain generic manufacturers for alleged patent infringement of later-expiring patents, though success has been limited given the primary patent expiry. These actions aim to delay or challenge specific generic entries, but their impact on the overall market share is diminishing.
• Portfolio Extensions:
  • Fixed-Dose Combinations (FDCs): Novalab has developed and is marketing fixed-dose combinations that include atorvastatin. For instance, Novalipid (atorvastatin and amlodipine besylate) and Atorva-Plus (atorvastatin and ezetimibe) offer new patentable entities and may capture market share from patients requiring multiple lipid-lowering agents.
    • Novalipid:
      • Therapeutic Area: Dyslipidemia and Hypertension
      • Mechanism: Combines statin therapy with a calcium channel blocker.
      • Regulatory Status: Approved in major markets.
    • Atorva-Plus:
      • Therapeutic Area: Dyslipidemia
      • Mechanism: Combines statin therapy with a cholesterol absorption inhibitor.
      • Regulatory Status: Approved in major markets.
  • Modified Release Formulations: While original formulation patents have expired, Novalab has explored and potentially patented novel modified-release formulations designed to improve patient adherence or alter pharmacokinetic profiles. Specific details on such formulations and their patent protection are proprietary.
• Pipeline Development: Novalab is investing heavily in research and development for novel therapeutics in cardiovascular disease and other areas. This includes candidates targeting different mechanisms of action for dyslipidemia and other metabolic disorders, aiming to diversify its revenue base beyond the ATORVALIQ franchise.
• Geographic Expansion: Pursuing market entry and longer patent protection in emerging markets where ATORVALIQ’s patent expiry timeline may differ or where generic penetration is slower.

These strategies aim to preserve revenue streams from the ATORVALIQ franchise and build a sustainable business model independent of the original blockbuster drug.

What are the Key Risks and Opportunities for Investors?

Investing in pharmaceutical companies with legacy blockbuster drugs like ATORVALIQ presents distinct risk-reward profiles.

Risks:

• Generic Erosion: The primary risk is the continued and aggressive market penetration of generic atorvastatin, which drives down prices and volume for branded products.
• Patent Litigation Losses: Failed attempts to enforce remaining formulation or process patents can result in significant legal expenses with no offsetting benefit.
• Pipeline Failures: Dependence on the success of the R&D pipeline. Clinical trial failures or regulatory rejections of new drug candidates can significantly impact future revenue projections.
• Pricing Pressures: Increased scrutiny from payers (governments, insurance companies) and the public on drug pricing can affect both branded and generic product profitability.
• Competition from New Mechanisms: Development of entirely new drug classes for dyslipidemia that offer superior efficacy or safety profiles could render existing statin therapies, including ATORVALIQ and its FDCs, less competitive.
• Manufacturing Costs: Maintaining competitive manufacturing costs for both branded and generic versions of atorvastatin is crucial in a price-sensitive market.

Opportunities:

• Successful FDC Launches: If Novalab's fixed-dose combinations gain significant market traction and capture market share from single-agent statins and other combination therapies, they can provide a valuable revenue stream.
• Pipeline Success: A successful launch of a novel drug candidate from Novalab's R&D pipeline, particularly one addressing unmet needs in cardiovascular disease, could drive substantial growth and offset declining ATORVALIQ revenues.
• Emerging Markets: Continued expansion and market share gains in emerging markets where patent cliffs are more recent or regulatory pathways are less mature.
• Strategic Partnerships and Acquisitions: Novalab could leverage its existing infrastructure and cash flow to acquire smaller biotechs with promising pipelines or enter into strategic partnerships for co-development or co-marketing.
• Efficient Generic Operations: If Novalab also participates in the generic atorvastatin market, it can capture a portion of that revenue stream, although margins are significantly lower.

Investment decisions should consider the balance between the diminishing revenue from ATORVALIQ and the potential of Novalab's next-generation products and strategic initiatives.

Key Takeaways

ATORVALIQ’s patent expiry has led to significant generic competition, impacting Novalab Pharmaceuticals' revenue from the drug. Novalab is mitigating this by developing fixed-dose combinations and investing in its R&D pipeline. Investors face risks from generic erosion and pipeline failures, alongside opportunities in successful FDC launches and new drug approvals.

FAQs

What are the implications of ATORVALIQ's patent expiry for patient access to affordable medication?

The expiry of ATORVALIQ’s composition of matter patent and subsequent related patents has enabled the widespread availability of generic atorvastatin calcium. This competition has drastically reduced the cost of the drug, significantly improving patient access to effective cholesterol-lowering therapy.

How does Novalab Pharmaceuticals differentiate its branded ATORVALIQ from generic versions?

Novalab differentiates its branded ATORVALIQ primarily through marketing, patient support programs, and potentially through its portfolio of fixed-dose combinations (FDCs) that include atorvastatin. These FDCs, such as Novalipid and Atorva-Plus, offer unique therapeutic benefits and have their own patent protections, allowing them to command a premium over single-agent generics.

What is the typical market lifespan for a blockbuster drug after its primary patent expires?

Following the expiry of the primary composition of matter patent, a blockbuster drug typically experiences rapid market share erosion due to generic competition. Branded sales can decline by 80-90% within the first few years. The remaining market share for the branded product is often limited to specific patient populations or preferences, or it is maintained through combination products or novel formulations.

How does the regulatory landscape in emerging markets affect ATORVALIQ's patent protection and generic competition?

Regulatory landscapes in emerging markets can vary significantly. Patent laws may be less robust, or enforcement may be weaker, potentially leading to earlier generic entry or more lenient conditions for generic approvals. Conversely, some emerging markets may have longer patent protection periods or different data exclusivity rules, allowing Novalab to maintain a branded presence for a longer duration compared to highly developed markets.

What is the future outlook for statin therapy in light of new drug development for dyslipidemia?

While statins, including atorvastatin, remain a cornerstone of dyslipidemia management due to their efficacy, safety, and cost-effectiveness, new drug development is introducing alternative mechanisms of action. These include PCSK9 inhibitors, bempedoic acid, and inclisiran, which target different pathways involved in lipid metabolism. These novel agents are often positioned for patients who are statin-intolerant or have refractory hypercholesterolemia, suggesting a future where statins coexist with, rather than are entirely replaced by, newer therapeutic classes.

Citations

[1] Pfizer Inc. (2009). Pfizer Inc. Annual Report 2008. Retrieved from [Link to hypothetical annual report, e.g., SEC filings]